Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Grass pollen-derived allergy immunotherapeutic - DMS Imaging

Next Previous
Drug Profile

Grass pollen-derived allergy immunotherapeutic - DMS Imaging

Alternative Names: ABT-011; gp-ASIT+™; gpASIT+; Grass-pollen-allergy-immunotherapy-DMS Imaging; Grass-pollen-allergy-vaccine-DMS Imaging; Grass-pollen-extract-DMS Imaging; Oral-grass-pollen-allergy-vaccine-DMS Imaging

Latest Information Update: 29 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioTech Tools
  • Developer DMS Imaging
  • Class Allergens; Allergy immunotherapies; Antiallergics; Peptides; Plant allergy immunotherapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Allergic rhinoconjunctivitis

Highest Development Phases

  • Discontinued Allergic rhinoconjunctivitis

Most Recent Events

  • 31 Jan 2021 Discontinued - Phase-II for Allergic rhinoconjunctivitis in Luxembourg, Belgium, France (PO) before January 2021
  • 31 Jan 2021 Discontinued - Phase-III for Allergic rhinoconjunctivitis in Czech Republic, Spain, France, Germany, Italy, Hungary, Poland, Belgium (SC) before January 2021
  • 17 Oct 2019 Adverse events and efficacy data from phase III trial in Allergic rhinoconjunctivitis presented in the Journal of Allergy and Clinical Immunology (JACI-2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top